CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it ...